PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety and maximum tolerated dose of
PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of
PCI-24781 when used in combination with doxorubicin (phase II) in patients with advanced
sarcomas. The study drug, PCI-24781, is believed to regulate genes involved in tumor cell
growth. The other study drug, doxorubicin, is considered a standard chemotherapeutic
treatment for advanced sarcoma patients. We hypothesize that combining PCI-24781 with
doxorubicin can overcome chemoresistance to doxorubicin.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Pharmacyclics LLC.